We already know that targeted therapy sequenced with immunotherapy not only has an impact on efficacy (one study showed that the addition of immunotherapy to targeted therapy improved the prognostic outcome of patients with HER2-positive gastric cancer (Killock 2022). This evidence concerns the gene ERBB2 and gastric cancer.